| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
82,823,000 |
| Market
Cap: |
1.83(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$18.92 - $29.92 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 484 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Veracyte is a genomic diagnostics company. Co. develops tests that address clinical needs in the diagnosis, prognosis and treatment of cancer and other diseases. Co. provides tests in: thyroid cancer via its Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas; prostate cancer via its Decipher Biopsy and Radical Prostatectomy Genomic Classifiers; breast cancer via its Prosigna Breast Cancer Assay; lung cancer via its Percepta GSC and Percepta Nasal Swab Test; interstitial lung diseases including idiopathic pulmonary fibrosis via its Envisia Genomic Classifier; bladder cancer via its Decipher Bladder Genomic Classifier; and colon cancer via its Immunoscore Colon Cancer Test.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
11,539 |
21,539 |
104,169 |
521,685 |
| Total Sell Value |
$248,847 |
$492,446 |
$2,960,641 |
$13,780,081 |
| Total People Sold |
2 |
3 |
4 |
7 |
| Total Sell Transactions |
2 |
3 |
12 |
30 |
| End Date |
2024-03-14 |
2023-12-12 |
2023-06-13 |
2022-06-13 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Anderson Bonnie H |
Chairman and CEO |
• • – |
2019-09-03 |
4 |
D |
$25.09 |
$24,789 |
D/D |
(988) |
112,426 |
|
- |
|
| Ho Mark |
Principal Accounting Officer |
– – – |
2019-09-03 |
4 |
D |
$25.09 |
$1,656 |
D/D |
(66) |
21,823 |
|
- |
|
| Jones Evan/ Fa |
Director |
– • – |
2019-08-28 |
4 |
S |
$26.10 |
$172,290 |
I/I |
(6,600) |
179,653 |
|
- |
|
| Jones Evan/ Fa |
Director |
– • – |
2019-08-27 |
4 |
S |
$26.11 |
$88,760 |
I/I |
(3,400) |
186,253 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2019-08-13 |
4 |
AS |
$25.45 |
$118,088 |
D/D |
(4,640) |
48,037 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2019-08-13 |
4 |
OE |
$10.45 |
$48,488 |
D/D |
4,640 |
52,677 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2019-08-12 |
4 |
AS |
$25.38 |
$717,095 |
D/D |
(28,257) |
48,037 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2019-08-12 |
4 |
OE |
$5.43 |
$232,095 |
D/D |
27,962 |
76,294 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2019-08-12 |
4 |
AS |
$25.28 |
$202,237 |
D/D |
(8,000) |
113,414 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2019-08-12 |
4 |
OE |
$2.68 |
$3,910 |
D/D |
1,459 |
121,414 |
|
- |
|
| Jones Evan/ Fa |
Director |
– • – |
2019-08-09 |
4 |
S |
$26.38 |
$395,681 |
I/I |
(15,000) |
189,653 |
|
- |
|
| Cohen Fred E |
Director |
– • – |
2019-08-02 |
4 |
OE |
$5.28 |
$368,200 |
D/D |
40,000 |
40,000 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2019-07-10 |
4 |
AS |
$28.78 |
$230,314 |
D/D |
(8,000) |
119,955 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2019-07-10 |
4 |
OE |
$2.68 |
$21,440 |
D/D |
8,000 |
127,955 |
|
- |
|
| Kennedy Keith |
COO / CFO |
• – – |
2019-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
87,211 |
|
- |
|
| Hanna John Walter Jr |
Chief Commercial OfficerOffice |
• – – |
2019-06-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
65,357 |
|
- |
|
| Ho Mark |
|
– – – |
2019-06-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
21,187 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2019-06-10 |
4 |
AS |
$26.33 |
$210,635 |
D/D |
(8,000) |
119,955 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2019-06-10 |
4 |
OE |
$2.68 |
$21,440 |
D/D |
8,000 |
127,955 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2019-06-04 |
4 |
OE |
$2.36 |
$60,536 |
D/D |
25,651 |
119,955 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2019-06-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(292) |
48,332 |
|
- |
|
| Hall Christopher M |
President and COO |
• – – |
2019-06-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(456) |
28,258 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2019-06-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(988) |
94,304 |
|
- |
|
| Kennedy Keith |
Chief Financial Officer |
• – – |
2019-06-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(339) |
71,211 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2019-05-10 |
4 |
AS |
$22.77 |
$183,948 |
D/D |
(8,000) |
95,292 |
|
- |
|
524 Records found
|
|
Page 15 of 21 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.78 (3.66%) 
